What Human Bioplazma does

Human BioPlazma Kft. is a Hungarian limited liability company and wholly-owned subsidiary of Kedrion Biopharma (Kedrion S.p.A.), an Italian multinational biopharmaceutical group. The entity operates the Gödöllő production facility, located approximately 30 km from Budapest, which specializes in plasma fractionation with a stated annual capacity of 600,000 liters. The plant was originally established in 1924 under the HUMAN brand to develop sera and vaccines for human use, and it celebrated its 100th anniversary in 2024. Within Kedrion's broader industrial footprint, the Gödöllő site focuses on producing intermediates for immunoglobulins and human albumin, which are subsequently processed and distributed as part of Kedrion's portfolio of 38 plasma-derived therapeutics targeting coagulation disorders, neurological disorders, immunodeficiencies, and Rh sensitization.

The underlying technology is conventional industrial plasma fractionation (Cohn-style and chromatography-based separation) used to derive therapeutic protein fractions from pooled human plasma collected at apheresis centers. Human BioPlazma itself does not operate plasma collection sites; raw plasma is sourced through Kedrion's wider network, which includes 68 KEDPLASMA centers in the United States and 8 UNICAplasma centers in the Czech Republic, supplemented by third-party collection arrangements. The subsidiary holds current ISO 45001:2023 (occupational health and safety) and ISO 14001:2015 (environmental management) certifications issued by SGS, and the legal entity is registered with Budapest Környéki Törvényszék Cégbírósága under registration number 13-09-113455.

The business model is a B2B pharmaceutical distribution model embedded within Kedrion's global go-to-market. Plasma-derived products move through medical and healthcare channels — hospitals, specialty pharmacies, treatment centers, and patient advocacy channels — across more than 100 countries. Revenue is generated through one-time product sales to institutional healthcare buyers under quote-based or tender arrangements typical for plasma-derived therapeutics; pricing is not publicly disclosed. The customer base is the rare-disease patient population served through these institutional channels, with the subsidiary serving as a manufacturing node within the parent group's vertically integrated supply chain rather than as an independent commercial entity.

Name

Human Bioplazma

Legal name

Human BioPlazma Kft.

Website

https://kedrion.hu

Company type

Private

Founded year

1924

Operating status

Operating

Headcount range

251–500 employees

Short description

Human BioPlazma Kft. is the Hungarian subsidiary of Kedrion Biopharma, operating a 600,000-liter plasma fractionation facility in Gödöllő, Hungary, producing immunoglobulin and albumin intermediates for Kedrion's portfolio of rare-disease therapies distributed globally.

Ownership category

akta.pro rank

Product category

Plasma-derived biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

Keywords

• Plasma-derived therapies
• Plasma fractionation
• Biopharmaceutical manufacturing
• Rare disease treatments
• Immunoglobulin production

Headquarters

HQ city

Godollo

HQ country

Hungary

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Others

Revenue model

1. Plasma-derived pharmaceutical products: The company generates revenue through the development, manufacturing, and distribution of plasma-derived therapies. These include products for coagulation disorders, neurological disorders, immunodeficiencies, and Rh sensitization. The company manufactures and sells 38 life-enhancing and life-saving products globally.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Human Bioplazma manufactures plasma-derived pharmaceutical products at its Gödöllő facility, including immunoglobulins and human albumin intermediates, used to treat rare and ultra-rare diseases such as coagulation disorders, neurological disorders, immunodeficiencies, and Rh sensitization. Operating as a wholly-owned subsidiary of Kedrion Biopharma, the facility contributes to a global portfolio of 38 plasma-derived products distributed in over 100 countries with a 600,000 liter fractionation capacity.

Product overview

Human BioPlazma Kft is the Hungarian subsidiary of Kedrion Biopharma, continuing the legacy of HUMAN established in 1924. The company's core product offering consists of plasma-derived therapies manufactured at its Gödöllő facility, including immunoglobulins and human albumin intermediates. As part of Kedrion's global network, it distributes 38 life-enhancing and life-saving products in over 100 countries. The subsidiary operates alongside 68 KEDPLASMA collection centers in the US and 8 UNICAplasma centers in the Czech Republic.

Differentiator

Problem solved

Functional benefit

Products and services

• Plasma-Derived Therapies Plasma-derived medicinal products including immunoglobulins and human albumin intermediates produced at the Gödöllő facility, used to treat rare and ultra-rare diseases such as coagulation disorders, neurological disorders, immunodeficiencies, and Rh sensitization.
• KEDPLASMA Plasma Collection Centers Network of 68 plasma collection centers operated by KEDPLASMA in the United States that collect source plasma for fractionation into plasma-derived therapies.
• UNICAplasma Centers Network of 8 plasma collection centers managed by UNICAplasma in the Czech Republic that collect source plasma for fractionation.

Quantifiable outcome

• 38 life-enhancing and life-saving products available globally
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Medical and Scientific CommunitycoreStrategic or Co-development PartnerPartnership with medical and scientific communities to drive sustainable innovation and improve patient care for rare disease treatments. Collaboration includes clinical research, treatment development, and medical education initiatives.
• Patient Advocacy GroupscoreStrategic or Co-development PartnerPartnership with patient advocacy groups to better understand patient needs, support rare disease communities, and improve patient care. These collaborations help ensure patient perspectives are integrated into treatment development.
• Research OrganizationscoreStrategic or Co-development PartnerCollaboration with research institutions to advance plasma-derived therapy development and innovation in rare disease treatments. Working together to develop new solutions for unmet medical needs.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• CSL Behring: Global leader in plasma-derived therapies and subsidiary of CSL Limited. Directly comparable in plasma collection, fractionation, and specialty biologics for rare diseases including immunodeficiencies and coagulation disorders.
• Takeda Pharmaceutical (Plasma-Derived Therapies): Japanese pharma major with a major plasma-derived therapy franchise (inherited from Shire/Baxalta). Directly competes in immunoglobulin and rare disease plasma therapeutics globally.
• LFB (Laboratoire Français du Fractionnement et des Biotechnologies): French state-linked plasma fractionator producing plasma-derived medicinal products including immunoglobulins and coagulation factors. Comparable in plasma fractionation and rare disease therapeutics.
• Kedrion Biopharma: Italian parent company and the 5th largest plasma fractionator globally. Human BioPlazma is its wholly-owned Hungarian subsidiary; directly comparable in plasma fractionation, immunoglobulin production, and global plasma-derived therapy distribution.
• Grifols: Spanish multinational and one of the world's top three plasma fractionators. Directly comparable in plasma collection network scale, fractionation capacity, and therapeutic immunoglobulin/albumin product portfolio.
• Octapharma: Swiss private plasma fractionator producing immunoglobulins, coagulation factors, and albumin. Closely comparable in plasma-derived product portfolio and European manufacturing footprint.
• Biotest: German specialty plasma protein manufacturer producing immunoglobulins, clotting factors, and albumin. Comparable European plasma fractionator focused on rare diseases.

Broad incumbents

• Pfizer: Global pharmaceutical incumbent with rare disease and biologics portfolios. Broad competitor in plasma-derived and recombinant therapeutic protein markets.
• Sanofi (Specialty Care / Rare Diseases): Global pharmaceutical major with a rare disease and specialty care franchise. Adjacent competitor in rare disease therapeutics including enzyme replacement and immunoglobulin therapies.

Emerging players

• ADMA Biologics: US-based specialty immune globulin manufacturer focused on primary immunodeficiencies. Comparable in plasma-derived immunoglobulin focus but smaller scale and single-site operations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Human Bioplazma